Free Trial

JanOne Q2 2023 Earnings Report

JanOne EPS Results

Actual EPS
$0.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

JanOne Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

JanOne Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

⭕ [URGENT] Buy Alert just triggered (Ad)

My absolute favorite stock just hit a critical "buy now" trigger price.

Click here for the ticker >>>
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like JanOne? Sign up for Earnings360's daily newsletter to receive timely earnings updates on JanOne and other key companies, straight to your email.

About JanOne

JanOne (NASDAQ:JAN), a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through Biotechnology and Recycling segments. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.

View JanOne Profile

More Earnings Resources from MarketBeat

Upcoming Earnings